Chemokines are a family of 8-10 kDa proteins with a wide range of biological activities including the regulation of leukocyte trafficking, modulation of haemopoietic cell proliferation and adhesion to extracellular matrix molecules. Using a panel of chemokine receptor-specific monoclonal antibodies (MoAb) in a multicolour flow cytometry approach we analysed the expression of the lymphocyte-associated chemokine receptors CXCR4, CXCR5, CCR5 and CCR6 in B cell acute lymphoblastic leukaemia (precursor B-ALL; six cases), B cell chronic lymphocytic leukaemia (B-CLL; 31 cases), multiple myeloma (10 cases), mantle cell lymphoma (MCL, four cases), follicular lymphoma (FL, three cases) and hairy cell leukaemia (HCL, five cases). We demonstrate that CXCR4, CXCR5 and CCR6 are differentially expressed in these B lymphoproliferative disorders depending on the maturational stage of the malignant B cell population investigated. In particular, we found that CXCR4 is strongly expressed on immature ALL blasts whereas no surface immunoreactivity for CXCR5, CCR5 and CCR6 was observed. By contrast, non-Hodgkin's lymphomas (NHLs) corresponding to more mature peripheral B cell subsets (ie B-CLL and MCL) exhibited high expression levels of CXCR4 and CXCR5. Analysis of terminally differentiated myeloma cells revealed a down-regulation of CXCR4, CXCR5 and CCR6. CCR5, which is not expressed in normal B cells, was also absent from the majority of NHLs. However, CCR5 staining was seen in three of five cases of HCL, representing the first example of cross-lineage aberrant chemokine receptor expression in malignant haemopoietic cells. Leukemia (2001) 15, 752-756.
Introduction
An efficient immune response is critically dependent on the presence of lymphocyte clones with the right antigen specificity at the site of inflammation. Many of the cues needed to direct lymphocytes into the right position are provided by members of the chemokine family that are produced and secreted in inflamed tissues. 1 In addition to their role in inflammation, chemokines have recently been shown to play an important role in the homing of circulating lymphocytes to secondary lymphoid organs, eg lymph nodes and Peyer's patches, under physiological conditions. 2 The specific effects of chemokines on their target cells are mediated by members of a family of 7-transmembrane-spanning G-protein-coupled receptors, 18 of which have been cloned and characterized in the past decade. 1 It is now well established that unique patterns of chemokine receptor expression may help define lymphocyte populations that differ in differentiation, activation stages and biological properties. 3, 4 Chemokine receptors previously implicated in B cell migration and proliferation include CXCR4, CXCR5 and CCR6. [5] [6] [7] There is accumulating evidence that apart from their physiologic functions, chemokine receptors may also be involved in the migration and dissemination of malignant haemopoietic cells. 8 The non-Hodgkin's lymphomas (NHLs) represent the malignant counterparts of normal lymphocytes, arrested at specific stages of maturation. Using a panel of chemokine receptor-specific antibodies directed against CXCR4, CXCR5, CCR5 and CCR6 (Table 1) in a multicolour flow cytometry approach, we investigated the expression pattern of these receptors in B cell malignancies of varying maturational stages.
Materials and methods

Patients and cells
Normal bone marrow (NBM) and peripheral blood (PB) was obtained from normal blood donors and donations for allogeneic transplantation and leftovers of routine diagnostic marrow aspirations from haematologically normal patients. Diagnosis was based on the Revised European American Lymphoma Classification. 9 All samples were taken with appropriate informed consent from the patients according to institutional guidelines.
Cell surface staining and flow cytometry
Fresh heparinised PB and BM samples were prepared for flow cytometry by ammonium chloride erythrocyte lysis (Orthomune Lysing Reagent; Ortho Diagnostic Systems, Raritan, NJ, USA). As a first step in all cases the immunophenotype was characterized using antibodies directed against CD19, CD10, CD79a, IgM, CD34, CD22, and light chains (all from DAKO, Glostrup, Denmark), CD38, CD56, CD4, CD8, CD3, CD11c (all from Becton Dickinson, Heidelberg, Germany), CD103, CD138 (from DPC Biermann, Bad Nauheim, Germany) CD5 (Immunotech, Marseille, France) employing a standard three-colour flow cytometry approach. 10 Chemokine receptor expression was subsequently analysed in well-defined B cell populations, usually containing more than 95% malignant cells. For chemokine receptor 
Statistical analysis
Data are expressed as mean ± s.e.m. Student's t-test was used to compare results between the indicated experimental groups.
Results
Using a flow cytometry assay we analysed the expression of CXCR4, CXCR5, CCR5 and CCR6 in normal as compared to malignant B cell populations from patients with precursor B-ALL, CLL, multiple myeloma, mantle cell lymphoma, follicular lymphoma and hairy cell leukaemia (Table 2) .
Chemokine receptor immunostaining in normal PB and NBM-derived B cells
In line with previous reports 12 we found that CXCR4 is expressed at comparable levels in PB and NBM B cells (Table 2 , P Ͼ 0.05). All PB B cells expressed CXCR5, whereas in NBM two distinct B cell populations, a large CXCR5 positive one and a smaller CXCR5 negative one, could be detected Table 2 Chemokine receptor expression in B cell malignancies Flow cytometric detection using MoAbs described in Materials and methods with gating on CD19 + lymphocytes; data are percentages of CD19 + B lymphocytes co-expressing the indicated chemokine receptor, mean ± standard error; numbers in brackets denote positive cases of n tested. (Figure 1c) .
We have recently demonstrated that there is a significant up-regulation of CXCR4 as bone marrow progenitor cells develop from CD34
+ to more mature B lymphocytes. 14 While 57.7 ± 3.5% of NBM CD34
+ cells stained positive for CXCR4 (n = 23 14 ), no CXCR5, CCR6 and CCR5 expression (5.3 ± 0.8, 8.5 ± 1.4 and 6.0 ± 3.1%, respectively, n = 3, data not shown) was detected in these cells using flow cytometry.
Chemokine receptor immunostaining in B-precursor ALL
CXCR4 was the only chemokine receptor detected in six cases of B-precursor ALL (Table 2 ). CXCR4 expression levels on CD34 + ALL blasts were significantly higher than those reported for unfractionated NBM CD34 
/CD19
+ /CD10 + cells isolated from CML patients with B lymphoid blastic crisis, 14 suggesting that CXCR4 up-regulation may be a common phenomenon in normal and malignant early B lymphopoiesis.
Chemokine receptor immunostaining in B-CLL
All B-CLL cases exhibited a CXCR4 and CXCR5 positive phenotype with significantly stronger expression of CXCR4 in comparison to normal B cells (P Ͻ 0.05). In contrast to the homogenous expression pattern observed for CXCR4 and CXCR5, CCR6 surface immunoreactivity on CLL cells was highly variable, ranging from 2.1 to 100% of CD19 + /CD5 + cells. As a recent report has suggested that CLL can be subdivided into two biologically different groups according to CD38 expression, 15 we correlated CD38 expression with the percentage of cells staining positive for CXCR4, CXCR5 and CCR6. No positive correlation was observed in either group.
To determine whether CCR6 expression may serve as a diagnostic factor identifying clinical subsets of patients with favourable vs poor prognoses, we compared the CCR6 + staining of B-CLL cells in patients with different clinical stages of the disease. The percentages of CCR6 + B-CLL cells in the Binet A (n = 9), B (n = 3) and C (n = 6) patient cohorts were 49.5 ± 8.9, 22.1 ± 10.0 and 41.2 ± 16.5%, respectively (P Ͼ 0.05).
Chemokine receptor immunostaining in multiple myeloma
Comparing CD138 positive malignant plasma cells to NBM B cells a significant down-regulation of CXCR4, CXCR5 and CCR6 was observed (P Ͻ 0.05) in the majority of patients (Table 2) . While the percentage of plasma cells co-expressing CXCR4 ranged from 5.9 to 100%, CXCR5 and CCR6 were not detectable in any of the samples analysed.
Chemokine receptor immunostaining in mantle cell lymphoma and follicular lymphoma
Both lymphoma entities expressed CXCR4 and CXCR5, whereas CCR5 immunoreactivity was absent. In analogy to the B-CLL data CCR6 expression in mantle cell lymphoma showed high interindividual variability (ranging from 20 to 100%).
Chemokine receptor immunostaining in hairy cell leukaemia (HCL)
CXCR4 and CCR6 expression was not significantly different from that of normal B cells. By contrast, CXCR5 immunostaining was reduced (P Ͻ 0.05) and dot plot analysis in all five cases tested revealed two distinct populations (Figure 1 ), representing residual normal peripheral B cells (staining brightly positive for CXCR5, Figure 2 ) and HCL cells (CXCR5 dim to intermediate, Figure 2 ). In 3/5 cases, HCL cells were found to express CCR5 (patients FS, RG and JK, Figure 1a) . Threecolour analysis (Figure 3 ) confirmed that CCR5 expression was restricted to the CD19 +
/CD11c
+ HCL cell population, whereas residual normal (CD11c negative) B cells in the same sample did not exhibit CCR5 immunoreactivity (Figure 3 ).
Discussion
Employing a panel of chemokine receptor-specific antibodies directed against CXCR4, CXCR5, CCR6 and CCR5 in a multicolour flow cytometry approach we show that malignant B cells corresponding to different stages of B cell development exhibit differential chemokine receptor expression patterns.
In accordance with previous studies 12, 14 our data demonstrate that CXCR4 is expressed in immature haemopoietic pro- 
/CD10
+ ALL cells was comparable to that of CD34 + /CD10 + NBM immature lymphoid progenitor cells, 14 suggesting that CXCR4 up-regulation may be a common phenomenon in normal and malignant early B lymphopoiesis. CXCR4 expression levels in B-CLL were higher than in the respective PB B cell controls confirming a recent study by Mö hle et al 16 showing CXCR4 overexpression in B-CLL. Furthermore, we found that CXCR4 is down-regulated in multiple myeloma complementing results recently reported for normal plasma cells. 17 By contrast, CXCR5 was not detected on immature normal and leukemic B lymphoid progenitor cells but was strongly expressed by essentially all PB B cells and leukemic B lymLeukemia phomas with a nodular dissemination pattern (eg B-CLL, MCL, follicular lymphoma). These observations are consistent with a report by Fö rster et al 13 showing that CXCR5 expression defines mature recirculating B cells but is absent from early bone marrow lymphoid precursor cells. Furthermore, our finding that CXCR5 expression is particularly high in nonHodgkin's lymphomas with lymph node involvement supports the concept that CXCR5 and its ligand B cell-attracting chemokine-1 (BCA-1) may be involved in the homing of circulating malignant B cells to lymphoid tissues. In this context it is worth mentioning that BCA-1 is specifically expressed in B cell follicles, presumably by follicular dendritic cells (FDC 18 ). Disruption of CXCR5 in transgenic mice leads to disturbed development of primary follicles and Peyer's patches, 19 underscoring the functional importance of CXCR5/BCA-1 in B lymphocyte homing under physiological conditions. Interestingly, we show that CXCR5 is down-regulated in HCL and completely absent in multiple myeloma. This latter observation confirms earlier findings of Fö rster et al using Northern blot hybridisation in murine plasmacytoma cell lines 20 and flow cytometry in one patient with multiple myeloma 13 and extends them to a larger patient cohort. Our data showing weak or even absent staining for CXCR5 on HCL and ALL cells, respectively (Table 1) , contrast with those reported by Jones et al, 17 who demonstrated strong CXCR5 immunoreactivity on 30 cases of B cell lymphoma/leukemia corresponding to all maturational stages of B cell development. However, this discrepancy may be explained by differences in the experimental systems, the most important probably being the use of biotinylated CXCR5-specific antibodies by Jones et al 17 as compared to a directly PE-conjugated antibody in the present study.
CCR6 expression on normal mature circulating PB B cells was significantly higher than in NBM B cells, suggesting that CCR6 may be up-regulated in the course of B cell development. This observation is in accordance with a recent report by Bowman et al 4 demonstrating in a murine in vivo model that MIP-3␣ responsiveness and expression of its cognate receptor CCR6 are only acquired after emigration of B cells to the periphery. CCR6 was found to be absent on precursor B-ALL blasts and markedly expressed on all of the remaining lymphoma entities tested with the exception of multiple myeloma. Thus, its expression pattern in B cell tumours paralleled that observed for CXCR5, however, interindividual differences within the different lymphoma subgroups were more pronounced than those noted for CXCR5.
Unlike CXCR4, CXCR5 and CCR6, CCR5 has not been recognized as a B cell associated chemokine receptor 1, 5, 21 and its expression in normal haemopoietic cells appears to be restricted to T cells, monocytes and dendritic cells.
1 Consequently, our finding that CCR5 is not expressed in the majority of B cell non-Hodgkin's lymphomas was not unexpected. Notably, CCR5 was expressed in three out of five HCL cases (Figure 1 ) with no apparent association with the clinical stage of the disease. To our knowledge, this is the first example of a cross-lineage aberrant chemokine receptor expression described in a human lymphoproliferative disorder. Interestingly, one of these HCL patients in whom CCR5 expression was observed, received IFN-␣ on a regular basis. In light of our own recent results 22 demonstrating up-regulation of MIP-1␣ receptors in CD34
+ haemopoietic progenitor cells in response to IFN-␥, it appears possible that IFN-␣ treatment in these patients may have contributed to the up-regulation of CCR5 in the malignant HCL clone. To further investigate this possibility HCL cells isolated from an untreated patient with a CCR5 negative phenotype (HG, Figure 1) were cultured in the presence of varying concentrations of IFN-␣ (10 3 to 10 5 U/ml) for 24 h and subsequently analysed for CCR5 expression using flow cytometry. However, IFN-␣-treated cells did not exhibit increased CCR5 surface expression compared with that of normal controls (data not shown). Taken together, our findings raise several points. First, the pattern of chemokine receptor expression in normal B cells appears to be paralleled by that seen in B cell non-Hodgkin's lymphoma depending on the maturational stage of the cells investigated. In particular, while development of immature Blymphoid progenitors into more differentiated cells is associated with a step-like up-regulation of CXCR4, CXCR5 and CCR6, terminal differentiation of mature B cells results in down-regulation of these receptors. Second, CXCR5 which is known to play a pivotal role in normal B lymphocyte homing may also be involved in the dissemination of malignant B cells to lymphoid tissues. Thus, MoAbs aimed at this receptor may be used as a potential adjunct in the treatment of patients with CXCR5 positive non-Hodgkin's lymphomas. Third and finally, given the differential expression of chemokine receptors in different lymphoma entities, 17 chemokine receptor-specific antibodies may serve as diagnostic tools in the flow cytometric evaluation of non-Hodgkin's lymphomas.
In general, recent data have shown that receptor expression alone is not an adequate parameter to predict a cell's chemotactic potential. 4, 23 For instance, mature B cells express higher levels of CXCR4 receptors than uncommitted progenitors but exhibit a reduced chemotactic response to SDF-1␣ suggesting that signal transduction events downstream from CXCR4 may also regulate responsiveness of B cells to SDF-1␣. 23 Furthermore, our own previous work 14, 24 and that of others 25 has demonstrated that even in the presence of normal receptor levels aberrant responses to chemokines can be observed in malignant haemopoietic cells that may also be due to defects in intracellular signalling. Thus, the flow cytometric analysis of chemokine receptor expression described here needs to be complemented by functional studies investigating the biological response of lymphoma cells to the respective chemokines.
